Markets
Conceptual illustration with a figure standing amidst a variety of floating U.S. dollar bill fragments on a teal background
(Getty Images)
EPS SZN

The one group of people in markets who aren’t worrying about a recession

Earnings per share estimates are following a normal path ahead of the third-quarter reporting period, and 2025 profit forecasts are still going up.

Yiwen Lu

Corporate profitability is tethered to consumer welfare.

When estimated earnings per share (or EPS, a key measure of a company’s profitability) are revised higher, it’s generally a sign of solid economic times: workers have more more money to spend, so corporations make more. Vice versa for negative revisions, which suggest an economic soft patch where people are reducing spending and profits slide.

Thus, when everyone in the market is supposedly worrying about a bleak economic outlook, as has been the case lately, we should expect to see more downward pressure of EPS estimates. But the latest data compiled by FactSet suggests that analysts think that the economy is poised to keep chugging along. 

For all S&P 500 companies, bottom-up EPS estimates — that is, an aggregation of the company-by-company forecasts — for the third quarter of 2024 decreased by 2.8% from June 30 to August 31. These estimates go down heading into a reporting period, only for companies to then exceed expectations on a lowered bar. One quant once slammed earnings season as “cheating season” for this very reason.

But is a 2.8% cut to EPS estimates unusually large?

FactSet senior earnings analyst John Butters calculated the average decline of EPS estimates over the past 5, 10, 15 and 20 years and found that these ranged from 2.3% to 3.0%, meaning that the latest number sat fell around the middle of the range. 

What’s more, expectations about the future further down the road are still getting sunnier. Butters also noted that while during the first two months of the quarter, EPS estimates for the third quarter dropped, analysts bumped up their EPS estimates for calendar year 2025 by 0.3%.

More Markets

See all Markets
markets

Gene-editing stocks rally on Bloomberg report that FDA plans to fast-track approval process

Shares of biotechs working with gene-editing treatments rose after the industry’s top regulator told Bloomberg News that the Food and Drug Administration plans to publish a paper in early November outlining the agency’s new, faster approach to approving those treatments.

markets

Getty Images shares moon on licensing deal with Perplexity

Getty Images soared Friday after announcing a multiyear licensing deal with AI search company Perplexity AI. Reuters reports:

Under the agreement, Perplexity will integrate Getty’s API technology into its AI platform workflows, enabling users to access premium visuals while improving image attribution. The collaboration is part of a wider trend of digital platforms signing licensing deals with AI content providers to expand content access while respecting intellectual property rights and generating revenue.

Getty was up as much as 85% in the premarket trading session, but those gains are quickly dropping as holders rush to dump the stock, which has been a truly disastrous long-term trade.

In fact, Getty has had a pretty bizarre ride since it returned to the public markets on July 25, 2022, as part of a SPAC deal — in a previous life it had been publicly traded before being taken private in 2008. Within days of its return, Getty became a minor meme stock, spiking more than 250% before crashing a couple months later.

Since then, the stock’s trajectory has been abysmal. Prior to the announcement of the Perplexity AI deal on Friday, it was down 80% from its trading debut. No wonder people are trying to get out fast.

At last glance, those 85% gains in the premarket have been swamped by sellers, shrinking today’s gain for Getty down to 17%.

markets

AbbVie earnings beat estimates but sag on decline in oncology and aesthetics biz

AbbVie slipped after it reported earnings results that beat Wall Street estimates, but also showed a slowdown in its oncology and aesthetics business.

The company reported adjusted quarterly earnings per share of $1.86, compared to the $1.77 analysts polled by FactSet were expecting, and raised its full-year profit guidance. It also reported revenue at $15.7 billion, higher than the $15.5 billion the Street was penciling in.

But the pharmaceutical giant’s oncology and aesthetics business (sales of Botox and Juvederm) slowed down and missed the Street’s estimates. The latter is sometimes seen as a pulse for consumer sentiment.

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.